TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TCBP TC BioPharm

Post-Market Trading 01-08 18:46:31 EST

0.4050

-0.0110

-2.64%

盘后0.3851

-0.0199-4.91%

18:32 EST

High0.4300	Low0.3800	Vol664.76K
Open0.4200	D1 Closing0.4160	Amplitude12.02%
Mkt Cap4.16M	Tradable Cap4.15M	Total Shares10.26M
T/O267.70K	T/O Rate6.48%	Tradable Shares10.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TCBP","market":"US","secType":"STK","nameCN":"TC BioPharm","latestPrice":0.405,"timestamp":1736370000000,"preClose":0.416,"halted":0,"volume":664763,"hourTrading":{"tag":"盘后","latestPrice":0.3851,"preClose":0.405,"latestTime":"18:32 EST","volume":6522,"amount":2712.57689004,"timestamp":1736379150049},"delay":0,"floatShares":10256625,"shares":10259832,"eps":-131.56035,"marketStatus":"Post-Market Trading","change":-0.011,"latestTime":"01-08 18:46:31 EST","open":0.42,"high":0.43,"low":0.38,"amount":267698.4646688,"amplitude":0.120192,"askPrice":0.4,"askSize":93,"bidPrice":0.385,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-131.56035,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"adrRate":200,"listingDate":1644555600000,"exchange":"NASDAQ","adjPreClose":0.416,"preHourTrading":{"tag":"盘前","latestPrice":0.4189,"preClose":0.416,"latestTime":"09:28 EST","volume":15554,"amount":6946.572873239999,"timestamp":1736346481435},"postHourTrading":{"tag":"盘后","latestPrice":0.3851,"preClose":0.405,"latestTime":"18:32 EST","volume":6522,"amount":2712.57689004,"timestamp":1736379150049},"volumeRatio":0.358551},"requestUrl":"/m/hq/s/TCBP","defaultTab":"news","newsList":[{"id":"2502774777","title":"European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2502774777","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502774777?lang=en_us&edition=fundamental","pubTime":"2025-01-09 00:06","pubTimestamp":1736352362,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Wednesday morning, declining 0.49% to 1,307.19 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Genfit , which rose 5.3% and 4.8% respectively. They were followed by pharmaceutical company Novo Nordisk  and biopharmaceutical company argenx , which were up 2.2% and 1.9% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and semiconductor company Sequans Communications , which fell 7.9% and 5.2% respectively. They were followed by biotech firm Evaxion Biotech  and biopharmaceutical company Grifols , which dropped 2.8% and 2.4% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Amarin  and cruise line operator Carnival , which increased 2.7% and 0.6% respectively. They were followed by financial services company HSBC  and mining c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0417516738.SGD","LU0516423091.SGD","DBVT","BK4532","ADAP","BK4521","LU0164880469.USD","03143","NCNA","LU0889565916.HKD","BK4142","CUK","BK4107","EVAX","AMRN","LU1481107354.HKD","BK7104","LU0516422440.USD","LU1093756325.SGD","ARGX","LU0154236417.USD","BHP","LU0516422366.SGD","AFG","BK4168","BK7507","NVO","00005","BK4207","NVO.AU","TCBP","HSHD.SI","GNFT","BK1610","HSBC","CLLS","HSBA.UK","LU1093756168.USD","BK4139","GRFS","BHP.AU","BK4585","LU0540923850.HKD","BK4141","BK4505","BK4599","TRIB","SQNS","LU0516423174.USD"],"gpt_icon":1},{"id":"2501265046","title":"TCBP Trading Continues Unabated on Nasdaq Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2501265046","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501265046?lang=en_us&edition=fundamental","pubTime":"2025-01-07 02:30","pubTimestamp":1736188200,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, Jan. 6, 2025 /PRNewswire/ -- TC BioPharm  PLC  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares  has continued trading on the Nasdaq Global Select Market  under the ticker symbol 'TCBP'.There has been no halt in trading and shares are expected to continue trading unabated. This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy shares of the Company's common stock or any other securities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tcbp-trading-continues-unabated-nasdaq-183000170.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcbp-trading-continues-unabated-nasdaq-183000170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","NDAQ","TCBPW","BK4585","LU2210149790.SGD","LU2210150020.SGD","PHH","IE00BGHQF748.EUR","LU2095319765.USD",".IXIC","TCBP","BK4112","BK4139","TC","BK4588","BK4009","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2501558254","title":"European Equities Traded in US as American Depositary Receipts Surge on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2501558254","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501558254?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:16","pubTimestamp":1736180194,"startTime":"0","endTime":"0","summary":"European equities trading in the US as American depositary receipts were sharply higher late Monday morning, as the S&P Europe Select ADR Index rose 1.6% to 1,315.5.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and 3D printer company Materialise , which climbed 20% and 6% respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria  and semiconductor company Sequans Communications  that increased almost 5% and 3%, respectively.The worst decliners in continental Europe were pharmaceutical company Novo Nordisk  and consumer goods giant Unilever  losing roughly 2% each. They were followed by pharmaceutical company Ascendis Pharma  and Natuzzi , which were down nearly 2% and 1%, respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics,  and alcoholic beverage company Diageo , gaining 6% and 3%, respectively. They were followed by pharmaceutical company Silence Therape","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLN","BK7104","LU1093756325.SGD","BK4588","AKTX","BK4169","BK4585","ULVR.UK","DGE.UK","NTZ","TCBP","IE00BKVL7J92.USD","NVO","WPP.AU","PUK","BK4183","BK4139","UN","BK4117","BK4009","DEO","BK4023","LU0889565916.HKD","BBVA","BK4592","BK4162","LU0124676726.USD","BK4546","CLLS","LU0689626769.HKD","LU0320765992.SGD","NVO.AU","WPP","SQNS","BK4599","BK4141","LU0154236417.USD","TRIB","MTLS","BK4082","ASND","BK4095","LU1093756168.USD","BK4207","IE00BZ1G4Q59.USD","UL","AFG","BK4007","BK4107","AUTL"],"gpt_icon":1},{"id":"2500976332","title":"European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2500976332","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500976332?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:05","pubTimestamp":1735833923,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.57% to 1,294.83 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company VEON  and biotech firm Evaxion Biotech , which climbed 7.3% and 6.3% respectively. They were followed by petroleum refiner Equinor  and biopharmaceutical company Genfit , which rose 3.7% and 2.9% respectively.The decliners from continental Europe were led by financial services companies Banco Bilbao Vizcaya Argentaria  and Banco Santander , which fell 2.2% and 1.8% respectively. They were followed by semiconductor company Sequans Communications  and software firm SAP , which dropped 1.7% and 0.6% respectively.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics , which advanced 15%, followed by biotech firm Autolus Therapeutics  and biopharmaceutical company Adaptimmune Therapeutics , which rose 13% each. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0417516738.SGD","TCBP","00005","BK1610","GNFT","LU0164880469.USD","LU0823431647.USD","DEO","DAVA.AU","03143","LU1481107354.HKD","BK4169","BK4107","BK4201","HSBC","BK4521","DGE.UK","BK4117","BK4585","AFG","HSHD.SI","LU0540923850.HKD","ADAP","VEON","EQNR","SAP","LU2236285917.USD","AUTL","SAN.AU","BK4528","LU0149721374.USD","SLN","DAVA","LU0648005311.SGD","BK4588","SAN","HSBA.UK","BBVA","AMRN","BK7142","BK4207","BK4134","SQNS","BK4132","LU0634319403.HKD","EVAX","BK1601","BK4141","LU0950373646.USD","LU0348735423.USD"],"gpt_icon":0},{"id":"2500644691","title":"TC BioPharm Shares Rise as Talks With Acquisition Targets Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2500644691","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500644691?lang=en_us&edition=fundamental","pubTime":"2025-01-01 03:50","pubTimestamp":1735674651,"startTime":"0","endTime":"0","summary":"TC BioPharm  shares rose as much as almost 25% in recent trading Tuesday after the company said that negotiations with its acquisition targets are progressing.The company is looking to expand its therapeutic platform through acquisitions focusing on new indications and  cell therapy approaches.\"Management is currently negotiating deal terms in good faith, and I believe the process is progressing to mutually beneficial outcomes,\" TC BioPharm Chief Executive Bryan Kobel said.The company did not identify the acquisition candidates.Price: 0.64, Change: +0.03, Percent Change: +5.10","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TC","TCBP","BK4139"],"gpt_icon":0},{"id":"2495611357","title":"TC Biopharm advances negotiations with acquisition candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2495611357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495611357?lang=en_us&edition=fundamental","pubTime":"2024-12-31 23:20","pubTimestamp":1735658417,"startTime":"0","endTime":"0","summary":"TC BioPharm (TCBP) has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tc-biopharm-advances-negotiations-with-acquisition-candidates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tc-biopharm-advances-negotiations-with-acquisition-candidates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TC","TCBP","BK4009","BK4139"],"gpt_icon":0},{"id":"2495196616","title":"Press Release: TCBP Provides Update on Acquisition Strategy and Current Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2495196616","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495196616?lang=en_us&edition=fundamental","pubTime":"2024-12-31 23:15","pubTimestamp":1735658100,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, Dec. 31, 2024 /PRNewswire/ -- TC BioPharm  PLC   a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates.This past spring TCBP announced the execution of non-binding letters of intent as part of its M&A strategy aimed at expanding its therapeutic platform. The Company continues to pursue its expansion strategy via acquisition, specifically in new indications and new cell therapy modalities.TCBP will be focusing its acquisition efforts on two main areas; Natural Kill cell technologies and CAR-related technologies. The Company intends to move forward with near-term acquisition opportunities in the NK space, reviewing several new opportunities in the allogeneic NK space as well as the CAR-NK space. This would expand the Company's efforts into autoimmune disease as well as additional ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TC","TCBP","BK4009"],"gpt_icon":0},{"id":"2495572767","title":"TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2495572767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495572767?lang=en_us&edition=fundamental","pubTime":"2024-12-31 03:47","pubTimestamp":1735588046,"startTime":"0","endTime":"0","summary":"The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm conducted a general meeting on December 30, 2024, w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tc-biopharm-approves-key-resolutions-to-enhance-strategic-flexibility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tc-biopharm-approves-key-resolutions-to-enhance-strategic-flexibility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TC","BK4139","BK4009","TCBP"],"gpt_icon":0},{"id":"2495226635","title":"European Equities Traded in the US as American Depositary Fall in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2495226635","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495226635?lang=en_us&edition=fundamental","pubTime":"2024-12-31 00:10","pubTimestamp":1735575012,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving lower late Monday morning, declining 0.92% to 1,284.25 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and telecommunications company VEON , which advanced 12% and 5.8% respectively. They were followed by medical device maker EDAP  and petroleum refiner Equinor , which rose 2.1% and 0.6% respectively.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company Grifols , which fell 12% and 4.2% respectively. They were followed by 3D printer company Materialise  and furniture maker Natuzzi , which were down 3% and 2.6% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm  and Akari Therapeutics , which climbed 11% and 5.5% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals  and financial services company Llo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKTX","BK4546","BK4207","LYG","SLN","BK4201","BDRX","BK4585","BK4023","TRIB","EQNR","AMRN","CLLS","EDAP","BK4117","BK4082","LU0823431563.USD","BK4588","BK4007","AFG","TCBP","BK4521","NCNA","LU0950373646.USD","BK4139","VEON","GRFS","EVAX","BK4107","LU0823431647.USD","BK4132","NTZ","MTLS","BK4095"],"gpt_icon":0},{"id":"2495852439","title":"TC BioPharm Shareholders Approve Stock Dividend; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2495852439","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495852439?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:52","pubTimestamp":1735573976,"startTime":"0","endTime":"0","summary":"TC BioPharm  said Monday its shareholders have approved its special stock dividend.The company said the special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders on the record date of Jan. 2 will be delivered to shareholders on or about Jan. 6.TC BioPharm shares were rising past 4% in recent trading.Price: 0.74, Change: +0.03, Percent Change: +4.65","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TC","TCBP"],"gpt_icon":0},{"id":"2495521617","title":"TC Biopharm shareholders approve 25% stock dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2495521617","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495521617?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:35","pubTimestamp":1735572917,"startTime":"0","endTime":"0","summary":"TC BioPharm (TCBP) announced that shareholders have formally approved the recently announced 25% stock dividend. TC BioPharm declared that last wee...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tc-biopharm-shareholders-approve-25-stock-dividend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tc-biopharm-shareholders-approve-25-stock-dividend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TC","TCBP","BK4009","BK4139"],"gpt_icon":0},{"id":"2495529715","title":"TCBP Issues 25% Stock Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2495529715","media":"PR Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495529715?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:30","pubTimestamp":1735572600,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm  PLC  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.Today, TC BioPharmdeclared that last week'sproposed special stock dividendwas formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares  for every 1 ADS held by shareholders on the record date of January 2, 2025 are expected to be delivered to shareholders on or about January 6th.TC BioPharm CEO, Bryan Kobel stated: \"Rewarding additional shares to shareholders in the form of this special dividend is an important and effective component of our capital management strategy. It also reflects management's strong confidence in the Company's financial future. I anticipate 2025 to be a period of growth and development for our Company as we ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tcbp-issues-25-stock-dividend-153000204.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcbp-issues-25-stock-dividend-153000204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TC","BK4009","TCBPW","TCBP"],"gpt_icon":0},{"id":"2494382228","title":"European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2494382228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494382228?lang=en_us&edition=fundamental","pubTime":"2024-12-28 00:07","pubTimestamp":1735315642,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were edging 0.03% lower late Friday morning to 1,298.5 on the S&P Europe Select ADR Index, which is up nearly 3% for the week.From co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0300736492.USD","NCNA","DBVT","BK4023","LU0300736062.USD","BK4546","OPRA","LU0098860793.USD","LU0278409577.USD","GRFS","BK4139","CLLS","BK4201","BK4117","LU0320765646.SGD","TRIB","MREO","BK4095","BDRX","BK4585","AFG","BK4107","EVAX","TCBP","BK4082","AUTL","SNN","EDAP","BK4505","BK4588","LU1162221912.USD","NTZ","LU2236285917.USD","MTLS","SHEL"],"gpt_icon":0},{"id":"2494862821","title":"European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2494862821","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494862821?lang=en_us&edition=fundamental","pubTime":"2024-12-27 00:07","pubTimestamp":1735229238,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, edging 0.10% higher to 1,298.82 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by furniture maker Natuzzi  and medical device maker EDAP TMS , which climbed 18% and 7.3% respectively. They were followed by telecommunications company VEON  and biopharmaceutical company Genfit , which were up 2.5% each.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company DBV Technologies , which dropped 2.8% and 2.6% respectively. They were followed by accommodations booking company trivago  and 3D printer company Materialise , which were off 0.7% each.From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics  and biopharmaceutical company Verona Pharma , which increased 2.2% and 2% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics  and TC Biophar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFG","GNFT","BK4007","LU0823431563.USD","BK4107","BK4095","EDAP","VEON","EVAX","TRIB","TRVG","NTZ","LU0950373646.USD","BK4117","BK4132","AUTL","BK4082","LU0823431647.USD","SLN","DBVT","BK4077","BK4023","TCBP","AKTX","BCYC","VRNA","MTLS","ADAP","BK4546","BK4139"],"gpt_icon":0},{"id":"2493381767","title":"European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2493381767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493381767?lang=en_us&edition=fundamental","pubTime":"2024-12-24 00:04","pubTimestamp":1734969897,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending slightly lower late Monday morning, declining 0.16% to 1,278.01 on the S&P Europe Select ADR Index.From continental Eur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","CRTO","NTZ","BK4585","LU0648005311.SGD","AKTX","EDAP","BK4117","BK4023","BK4009","BK4588","EVAX","LU1093756325.SGD","NVO","VRNA","NVO.AU","BK4505","LU1093756168.USD","TCBP","BK4139","IE00BFMHRM44.USD","BK4599","BK4107","MTLS","BK7104","BK4007","AUTL","DAVA","SLN","IE00BZ1G4Q59.USD","BK4546","DAVA.AU","BK4082","BK4077","IE00BKVL7J92.USD","BK4141","TRVG","BK4142","SQNS","LU0154236417.USD","BK4532","CUK","AFG","BK4095","LU0084288595.USD","MREO"],"gpt_icon":1},{"id":"2492451114","title":"TC Biopharm advances ACHIEVE Phase 2b clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492451114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492451114?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:35","pubTimestamp":1734701743,"startTime":"0","endTime":"0","summary":"TC BioPharm (TCBP) announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adver...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tc-biopharm-advances-achieve-phase-2b-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tc-biopharm-advances-achieve-phase-2b-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TC","BK4139","BK4009","TCBP"],"gpt_icon":0},{"id":"2492453104","title":"TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2492453104","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492453104?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:30","pubTimestamp":1734701400,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, Dec. 20, 2024 /PRNewswire/ -- TC BioPharm  PLC  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase2btrial in the UK with no drug-related Adverse Events seen in any of the restart patients.The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.\"As we progress with Cohort B, there is the potential for an expedited review given these patients' stage and disease expression,\" said Bryan Kobel, CEO of TC BioPharm. \"We believe minimal residual disease represents a high opportunity for TCB008 to be extremely impactful. We could see a response indicating high responsiveness in fewer than the currently proposed cohort size. At this trial stage, we are still collat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tcbp-advances-achieve-phase-2b-133000595.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcbp-advances-achieve-phase-2b-133000595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TC","BK4009","BK4139","TCBPW","TCBP"],"gpt_icon":0},{"id":"2492133357","title":"European Equities Traded in the US as American Depositary Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2492133357","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492133357?lang=en_us&edition=fundamental","pubTime":"2024-12-19 00:12","pubTimestamp":1734538373,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.18% to 1,338.75 on the S&P Europe Select ADR Index.From continental Europe, the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCYC","BK4107","BK7142","AFG","AZN","LU1829250122.USD","VOD","BK4007","BK4132","BK4117","SNY","IE00BFXG1179.USD","BK4588","DBVT","BK4082","EVAX","LU2236285917.USD","BK4585","AUTL","BK4532","LU2417539215.USD","PHG","SAN","BK4505","BK4568","TRIB","BBVA","BK4207","TCBP","LU0109394709.USD","LU2462157665.USD","BK4139","LU0889565916.HKD","SAN.AU","LU0320765992.SGD","BK4521","GNFT","MREO","EDAP","LU2456880835.USD"],"gpt_icon":0},{"id":"2492018530","title":"Press Release: TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2492018530","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492018530?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:30","pubTimestamp":1734528600,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm  PLC   a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares  for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders  at 2:00 p.m.  on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this Current Report on Form 6-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company's intent or ability to pay any dividends, affect any budget savings or ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TC","TCBP","BK4009","BK4139"],"gpt_icon":0},{"id":"2492183978","title":"EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183978","media":"Benzinga","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183978?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526818,"startTime":"0","endTime":"0","summary":"On Wednesday, TC BioPharm  PLC  announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval.The company intends to hold a general meeting of shareholders on Monday, December 30.The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the company's stock at the close of trading on January 02, 2025.\"We are extremely pleased to announce this special dividend, our shareholders have been supportive of the company through a difficult capital markets environment, including the Company being the target of a nefarious and false short and distort campaign,\" said Bryan Kobel, CEO of the Company.TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer with human efficacy data in acute myeloid leukemia.Gamma-delta T cells are naturally occurring immune cell","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y1MEyBuwTbjyBvgzg.XuKQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/838cf1fd8c4096f78bb11552012bd0d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y1MEyBuwTbjyBvgzg.XuKQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/838cf1fd8c4096f78bb11552012bd0d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-penny-stock-tc-biopharm-130018002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TCBPW","TCBP","TC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.tcbiopharm.com","stockEarnings":[{"period":"1week","weight":-0.1938},{"period":"1month","weight":-0.1983},{"period":"3month","weight":-0.8956},{"period":"6month","weight":-0.9374},{"period":"1year","weight":-0.9768},{"period":"ytd","weight":-0.1938}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.17336},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009909},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.047947},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.078542},{"month":5,"riseRate":0,"avgChangeRate":-0.336698},{"month":6,"riseRate":0,"avgChangeRate":-0.348963},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.039359},{"month":8,"riseRate":0,"avgChangeRate":-0.098609},{"month":9,"riseRate":0,"avgChangeRate":-0.144118},{"month":10,"riseRate":0,"avgChangeRate":-0.375054},{"month":11,"riseRate":0,"avgChangeRate":-0.393995},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.199908}],"exchange":"NASDAQ","name":"TC BioPharm","nameEN":"TC BioPharm"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TC BioPharm(TCBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TC BioPharm,TCBP,TC BioPharm股票,TC BioPharm股票老虎,TC BioPharm股票老虎国际,TC BioPharm行情,TC BioPharm股票行情,TC BioPharm股价,TC BioPharm股市,TC BioPharm股票价格,TC BioPharm股票交易,TC BioPharm股票购买,TC BioPharm股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TC BioPharm(TCBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}